Navigation
About
Vision & Mission
Leadership
SAB
Scientific Founders
Investors
Science
Pipeline
Platform
Library
Partnering
Business Development
Open-Innovation Laboratory
News
Activities
Company Milestones
Publications
Careers
Contact
Library
Library
Scientific
HFB200301
American Society of Clinical Oncology
|
April 27, 2022
Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™)
Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™)
Poster
American Association for Cancer Research
|
April 12, 2021
Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer
Publication
American Association for Cancer Research
|
July 03, 2020
Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment
Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment
Poster
HFB301001
European Society for Medical Oncology Congress
|
September 12, 2022
Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™)
Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™)
Poster
American Association for Cancer Research
|
April 12, 2021
Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
Publication
American Association for Cancer Research
|
July 03, 2020
HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy
HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy
Poster
HFB200603
American Association for Cancer Research
|
April 13, 2022
HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Poster
HFB200902
American Association for Cancer Research
|
April 12, 2021
HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers
Publication
Nature Scientific
|
March 04, 2021
Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model
Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model
Publication
American Association for Cancer Research
|
July 03, 2020
HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment
HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment
Poster
HFB101110
American Association for Cancer Research
|
April 18, 2022
Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Poster
HFB100204
American Association for Cancer Research
|
April 12, 2021
Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas
Publication
Platform
American Association for Cancer Research
|
April 08, 2022
Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Poster
Science Advances
|
June 11, 2021
High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics
High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics
Publication
American Association for Cancer Research
|
September 17, 2020
HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference
Publication
Nature Biotechnology
|
March 30, 2020
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
Publication
Nature Genetics
|
May 31, 2019
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Publication
Nature Biotechnology
|
September 11, 2017
Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring
Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring
Publication
HiFiBio, Paris
|
November 13, 2016
Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study
Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study
Poster
Strategy
Innovative Drug Discovery
Drug Discovery Today
|
May 2023
Global or local: The future of biotech
Global or local: The future of biotech
Publication
Drug Discovery Today
|
October 2017
Guiding principles of value creation through collaborative innovation in pharmaceutical research
Guiding principles of value creation through collaborative innovation in pharmaceutical research
Publication